Hisamitsu Pharmaceutical Co (FSE:4530) Other Current Assets: 円10,268 Mil (As of Nov. 2025)


FSE:4530 Hisamitsu Pharmaceutical Co Inc FSE:4530
89 GF Score
Price 円3,975.00
GF Value 円3,237.07
View Full Analysis

What is Hisamitsu Pharmaceutical Co Other Current Assets?

Hisamitsu Pharmaceutical Co FSE:4530 89 Other Current Assets is 円10,268 Mil as of Nov. 2025. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07.

Hisamitsu Pharmaceutical Co's other current assets for the quarter that ended in Nov. 2025 was 円10,268 Mil.

Hisamitsu Pharmaceutical Co's quarterly other current assets increased from May. 2025 (円6,745 Mil) to Aug. 2025 (円8,343 Mil) and increased from Aug. 2025 (円8,343 Mil) to Nov. 2025 (円10,268Mil).

Hisamitsu Pharmaceutical Co's annual other current assets increased from Feb. 2024 (円4,288 Mil) to Feb. 2025 (円5,058 Mil) declined from Feb. 2025 (円5,058 Mil) to Feb. 2026 (円4,771 Mil).


Hisamitsu Pharmaceutical Co Other Current Assets Related Terms


Hisamitsu Pharmaceutical Co Other Current Assets Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Other Current Assets Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,828.00 3,370.00 4,288.00 5,058.00 4,771.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,058.00 6,745.00 8,343.00 10,268.00 4,771.00
FSE:4530
89GF Score
Hisamitsu Pharmaceutical Co Inc FSE:4530
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of 円10,268 Mil mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a Other Current Assets of 円10,268 Mil as of Nov. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Hisamitsu Pharmaceutical Co.
Is Hisamitsu Pharmaceutical Co's Other Current Assets too high?
Hisamitsu Pharmaceutical Co's current Other Current Assets is 円10,268 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Other Current Assets compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Other Current Assets of 円10,268 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Hisamitsu Pharmaceutical Co. Hisamitsu Pharmaceutical Co's current Other Current Assets is 円10,268 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Other Current Assets of 円10,268 Mil. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Other Current Assets is 円10,268 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Other Current Assets is 円10,268 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

  • Other Current Assets: 円10,268 Mil
  • GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score

Get the complete analysis for FSE:4530

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00
Price
円3,237.07
GF Value